US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intensity Therapeutics, Inc.

1.91

-0.0300-1.55%

Post-market: 1.58-0.3300-17.28%19:10 EDT

Volume:15.10K

Turnover:28.01K

Market Cap:29.00M

PE:-1.63

High:1.94

Open:1.83

Low:1.81

Close:1.94

Loading ...

Overview Company News Filings

Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?

Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?

Press Release: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("Invincible-3 Study") Following Periodic Review

THOMSON REUTERS

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Intensity Therapeutics Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $8.5

THOMSON REUTERS

Intensity Therapeutics Provides Business Update Highlighting Key Achievements With Lead Drug Candidate Int230-6

THOMSON REUTERS

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares

MT Newswires Live

Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial

MT Newswires Live

Intensity Therapeutics reports positive results of INT230-6 in breast cancer

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Promising Clinical Progress and Financial Stability Drive Positive Outlook for Intensity Therapeutics, Inc.

BRIEF-Intensity Therapeutics Announces Pricing Of $3 Million Registered Direct Offering And Concurrent Private Placement

Intensity Therapeutics Inc - to Issue 1,237,113 Shares at $2.425 per Share

THOMSON REUTERS

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

THOMSON REUTERS

Press Release: Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Intensity Therapeutics presents INT230-6 Phase 1/2 daya in Sarcoma

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INTS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INTS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTS\",,,,,undefined,":{"symbol":"INTS","market":"US","secType":"STK","nameCN":"Intensity Therapeutics, Inc.","latestPrice":1.91,"timestamp":1745352000000,"preClose":1.94,"halted":0,"volume":15098,"hourTrading":{"tag":"盘后","latestPrice":1.58,"preClose":1.91,"latestTime":"19:10 EDT","volume":1325,"amount":2114.9100125,"timestamp":1745363457154},"delay":0,"floatShares":6856478,"shares":15180945,"eps":-1.169772,"marketStatus":"Post-Mkt","change":-0.03,"latestTime":"04-22 19:19:03 EDT","open":1.83,"high":1.94,"low":1.81,"amount":28008.859935800003,"amplitude":0.06701,"askPrice":1.88,"askSize":300,"bidPrice":1.36,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.169772,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":4,"adr":0,"listingDate":1666324800000,"exchange":"NASDAQ","adjPreClose":1.94,"postHourTrading":{"tag":"盘后","latestPrice":1.58,"preClose":1.91,"latestTime":"19:10 EDT","volume":1325,"amount":2114.9100125,"timestamp":1745363457154},"volumeRatio":1.255885},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTS\",,,,,undefined,":{"symbol":"INTS","floatShares":6856478,"roa":"-93.90%","roe":"-202.34%","lyrEps":-1.169772,"volumeRatio":1.255885,"shares":15180945,"dividePrice":0,"high":1.94,"amplitude":0.06701,"preClose":1.94,"low":1.81,"week52Low":1.5,"pbRate":"9.94","week52High":5.275,"institutionHeld":0,"latestPrice":1.91,"committee":-0.5,"eps":-1.169772,"divideRate":0,"volume":15098,"delay":0,"ttmEps":-1.169772,"open":1.83,"prevYearClose":1.76,"prevWeekClose":1.85,"prevMonthClose":1.97,"prevQuarterClose":1.97,"fiveDayClose":1.87,"twentyDayClose":2.05,"sixtyDayClose":2.4289},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INTS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529564382","title":"Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529564382","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529564382?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:40","pubTimestamp":1745242809,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Cencora  been one of those stocks this year?Let's take a closer look at the stock's year-to-date performance to find out.Cencora is a member of our Medical group, which includes 1002 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Cencora is currently sporting a Zacks Rank of #2 .Intensity Therapeutics Inc.  is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cencora-inc-cor-outperforming-other-134009430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["COR","INTS"],"gpt_icon":0},{"id":"2524136264","title":"Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524136264","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524136264?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:40","pubTimestamp":1743687611,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Cencora  been one of those stocks this year?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Cencora is a member of the Medical sector. This group includes 1005 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Cencora is currently sporting a Zacks Rank of #2 .Intensity Therapeutics Inc.  is another Medical stock that has o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cencora-inc-cor-outpaced-other-134011736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1261432733.SGD","LU2237957811.SGD","SGXZ23171101.USD","LU1430594728.SGD","BK4585","LU1585245621.USD","LU1084165304.USD","BK4529","BK4084","INTS","BK4139","BK4588","LU0058720904.USD","BK4175","LU1119994496.HKD","COR","LU2324357040.USD","LU0289739699.SGD","LU2237957902.USD","SG9999004303.SGD"],"gpt_icon":1},{"id":"2519869410","title":"Press Release: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519869410","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519869410?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:07","pubTimestamp":1741896420,"startTime":"0","endTime":"0","summary":"-- 32 sites are currently contracted in the INVINCIBLE-3 Study, and 25. -- Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several. Study design was presented at the annual Connective Tissue Oncology. INVINCIBLE-4 Study design was presented at the annual San Antonio Breast. In July 2024, the Company initiated and dosed its first patient in the INVINCIBLE-3 Study.  The trial is actively enrolling patients across the US, Canada, Europe and Australia. Up to 60 sarcoma-focused institutions are expected to participate from these regions. The Company has contracted 32 sites with 25 patients screened to date.  The Company expects to complete enrollment in the first half of 2026.In October 2024, in collaboration with The Swiss Group for Cancer Research SAKK , the Company initiated and dosed its first patient in Switzerland in the INVINCIBLE-4 Study. To date, the Company has activated eight sites in Switzerland and treat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348723411.USD","LU1861215975.USD","LU1861220033.SGD","LU0124384867.USD","INTS","LU0724618433.USD","LU1720051017.SGD","IE00BZ199S13.USD","BK4512","BK4588","IE00BD6J9T35.USD","LENZ","BK4605","LU1861214812.USD","BK4585","LU1854104046.USD","LU1978683503.SGD","LU1548497426.USD","BK4139","BK4141","LU1854103824.USD","LU2360107325.USD","ON","LU2298322129.HKD","LU2357305700.SGD","LU1720051108.HKD","LU1861219969.SGD"],"gpt_icon":0},{"id":"2506518045","title":"Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial (\"Invincible-3 Study\") Following Periodic Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2506518045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506518045?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nTUA1RF0W8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2506130975","title":"Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial (\"INVINCIBLE-3 Study\") Following Periodic Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2506130975","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506130975?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069200,"startTime":"0","endTime":"0","summary":"SHELTON, Conn., Jan. 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ,  a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that following its most recent periodic review meeting, the Data Monitoring Committee  overseeing the Company's ongoing Phase 3 sarcoma study of INT230-6   has agreed that the study should continue without modification. TheDMC reviewed data covering the six months from July to December 2024.\"The Data Monitoring Committee is designed to confidentially review data to determine whether safety concerns with the data collected to date exist. We are encouraged by the continuation of the trial and continue to believe that INT230-6 represents important potential in a treatment area that has significantly unmet medical need. We look forward to continuing enrollment and to providing furth","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/drug-monitoring-committee-authorizes-continuation-130000116.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/drug-monitoring-committee-authorizes-continuation-130000116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2517655291.USD","BK4134","BK4585","INTS","LENZ","LU0107464264.USD","LU0154245673.USD","LU2517655028.SGD","IT","LU1814569148.SGD","BK4588","LU2517655374.HKD","BK4139","LU0154245756.USD"],"gpt_icon":0},{"id":"2503930844","title":"Intensity Therapeutics Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $8.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2503930844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503930844?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:03","pubTimestamp":1736769780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O90YY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2502868288","title":"Intensity Therapeutics Provides Business Update Highlighting Key Achievements With Lead Drug Candidate Int230-6","url":"https://stock-news.laohu8.com/highlight/detail?id=2502868288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502868288?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA5RRXFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2502667865","title":"Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6","url":"https://stock-news.laohu8.com/highlight/detail?id=2502667865","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502667865?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":"The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study  in Metastatic Soft Tissue Sarcoma. Twenty-three sites are currently contracted in the INVINCIBLE 3 study, and several sites have treated patients. Seven Swiss sites are activated in the Phase 2  study for early-stage, operable Triple Negative Breast Cancer , and several patients have been treated. SHELTON, Conn., Jan. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announces a business update highlighting key achievements with its lead drug candidate INT230-6.In October 2024, the Company, in collaboration with the Swiss Group for Clinical Cancer Research SAKK  in the INVINCIBLE-4 Study,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/intensity-therapeutics-provides-business-highlighting-130000009.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intensity-therapeutics-provides-business-highlighting-130000009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","BK4131","INTS","CTOS","LU0061475181.USD","LU0149725797.USD","BK4534","LU0070302665.USD","UPS","LU1585245621.USD","LU2237438978.USD","IE0002270589.USD","BK4532","IE00BFSS7M15.SGD","LU1162221912.USD","LU0208291251.USD","PR","BK4559","IE00B19Z3B42.SGD","LENZ","LU2133065610.SGD","IE0004445015.USD","BK4588","IE00B19Z3581.USD","LU0211331839.USD","BK4104","IE00BFSS8Q28.SGD","IE00B7SZLL34.SGD","BK4585","LU0320765489.SGD","IE00BJJMRX11.SGD","BK4139","LU0320765646.SGD","BK4550","IE00BJJMRY28.SGD","LU1074936037.SGD","LU1430594728.SGD","IE00B7KXQ091.USD"],"gpt_icon":0},{"id":"2491958650","title":"Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2491958650","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491958650?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:48","pubTimestamp":1734126497,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics  said stockholder Armistice Capital may offer and resell almost 1.24 million shares.The shareholder will get all of the proceeds from any sales, Intensity Therapeutics said Friday in a regulatory filing.The timing and amount of any sale are at the sole discretion of Armistice.The shares of Intensity Therapeutics fell 2.9% in after-hours trading.Price: 2.00, Change: -0.06, Percent Change: -2.91","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","INTS","LENZ"],"gpt_icon":0},{"id":"2491336877","title":"Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2491336877","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491336877?lang=en_us&edition=fundamental","pubTime":"2024-12-13 00:26","pubTimestamp":1734020771,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics  and The Swiss Group for Clinical Cancer Research, or SAKK, said Thursday that cancer drug candidate INT230-6 showed several benefits in a phase 2 trial in multiple tumor types, including triple negative breast cancer.INT230-6, designed for direct intratumoral injection, leads to local disease control and direct tumor killing as well as has systemic anti-tumor effects, according to a joint statement.Data from the study showed that INT230-6 has tumor-killing properties at levels greater than 95% in some patients treated with a single dose, as well as \"significant\" necrosis in tumors bigger than 2 cm in 74% of the patients at the time of surgery, the company and SAKK said.Intensity and SAKK have also initiated a phase 2 study to assess the clinical activity, safety and tolerability of INT230-6 in patients with early-stage, operable triple negative breast cancer. Recruitment is ongoing, with a target to enroll 54 patients, and seven sites have been activated in Swit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","INTS","LENZ"],"gpt_icon":0},{"id":"2490835713","title":"Intensity Therapeutics reports positive results of INT230-6 in breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490835713","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490835713?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:10","pubTimestamp":1734009040,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics (INTS) and The Swiss Group for Clinical Cancer Research or SAKK, announced that Andreas Mueller presented the final data fro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-reports-positive-results-of-int230-6-in-breast-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-reports-positive-results-of-int230-6-in-breast-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4588","LENZ","BK4568","BNTX","INTS","BK4535","BK4551","BK4139","BK4585"],"gpt_icon":0},{"id":"2490830603","title":"Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490830603","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490830603?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:00","pubTimestamp":1734008400,"startTime":"0","endTime":"0","summary":"Enrollment is ongoing and seven sites in Switzerland have been activated. \"Women with aggressive forms of breast cancer, such as TNBC, are often counseled to undergo pre-surgical  systemic therapy in advance to reduce the risk of the disease returning. Having a pathological complete response, meaning the absence of live cancer at the time of surgery, has been shown to result in a lower risk of recurrence. When the tumor diameters are bigger than two centimeters, recurrence is more likely, so that neoadjuvant treatment is warranted\" said Dr. Mueller. \"If the immunological cancer cell death caused by INT230-6 and the ignition of an anti-cancer immune response without increased toxicity shows a meaningful increase in pCR, it would be a major advance for the neoadjuvant treatment of breast cancer and potentially other cancers. Further, if the results of this study are highly favorable, perhaps the cardiotoxic anthracycline drugs could be reduced or eliminated in future studies.\". The Compa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QlyJbPGPoLtUoNB9aBdoWw--~B/aD0xMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QlyJbPGPoLtUoNB9aBdoWw--~B/aD0xMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/intensity-therapeutics-inc-swiss-group-130000856.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intensity-therapeutics-inc-swiss-group-130000856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INTS","BK4139","BK4213","PR"],"gpt_icon":0},{"id":"2485194164","title":"Promising Clinical Progress and Financial Stability Drive Positive Outlook for Intensity Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2485194164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485194164?lang=en_us&edition=fundamental","pubTime":"2024-11-21 23:55","pubTimestamp":1732204514,"startTime":"0","endTime":"0","summary":"Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Intensity Therapeutics, Inc. (INTS – Research Report). The as...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-clinical-progress-and-financial-stability-drive-positive-outlook-for-intensity-therapeutics-inc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-clinical-progress-and-financial-stability-drive-positive-outlook-for-intensity-therapeutics-inc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INTS","PRGS","LU2065732104.USD","BK4139","BK4097"],"gpt_icon":0},{"id":"2485495931","title":"BRIEF-Intensity Therapeutics Announces Pricing Of $3 Million Registered Direct Offering And Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2485495931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485495931?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:13","pubTimestamp":1732194796,"startTime":"0","endTime":"0","summary":"Nov 21  - Intensity Therapeutics Inc   :   * INTENSITY THERAPEUTICS, INC. ANNOUNCES PRICING OF $3 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT   * INTENSITY THERAPEUTICS INC - TO ISSUE 1,237,113 SHARES AT $2.425 PER SHARESource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","INTS"],"gpt_icon":0},{"id":"2485549343","title":"Intensity Therapeutics Inc - to Issue 1,237,113 Shares at $2.425 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2485549343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485549343?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:00","pubTimestamp":1732194010,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA5BRYMF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2485149311","title":"Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2485149311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485149311?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:00","pubTimestamp":1732194010,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA5BRYMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2485493221","title":"Press Release: Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2485493221","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485493221?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:00","pubTimestamp":1732194000,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement. SHELTON, Conn., Nov. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ,  a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the issuance and sale of 1,237,113 shares of its common stock in a registered direct offering at a purchase price of $2.425 per share.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2484620184","title":"Intensity Therapeutics presents INT230-6 Phase 1/2 daya in Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2484620184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484620184?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:35","pubTimestamp":1731936943,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics (INTS) announced that Christian Meyer M.D., Ph.D., Assistant Professor of Oncology and lead medical oncologist for adult sar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-presents-int230-6-phase-1-2-daya-in-sarcoma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-presents-int230-6-phase-1-2-daya-in-sarcoma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INTS","BK4139","LENZ"],"gpt_icon":0},{"id":"2484622654","title":"Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial (\"INVINCIBLE-3 Study\") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622654","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622654?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"Phase 1/2 data showed a median overall survival  of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone. INVINCIBLE-3 Study is recruiting and expected to enroll 333 patients with leiomyosarcoma, liposarcoma and undeferential pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., Canada, Europe and Australia. \"The data in the Phase 1/2 study has shown that INT230-6 causes cell death leading to tumor necrosis, improved cancer recognition by immune cells, and an ignition of a systemic anti-cancer immune response that results in T-cells enteringthe tumor microenvironment and has shown a favorable safety profile in soft tissue sarcomas,\" said Dr. Razak. \"Systemically delivered chemotherapies have severe side effects, including cardiotoxicity, and most sarcoma subtypes have only a minimal response to immunotherapies. In addition, most sarcoma patients","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QlyJbPGPoLtUoNB9aBdoWw--~B/aD0xMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QlyJbPGPoLtUoNB9aBdoWw--~B/aD0xMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/intensity-therapeutics-presents-int230-6-130000048.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intensity-therapeutics-presents-int230-6-130000048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0154245673.USD","LU2517655291.USD","LU1814569148.SGD","BK4588","INTS","BK4134","LU0107464264.USD","LU0154245756.USD","BK4585","LENZ","BK4213","CTOS","LU2517655028.SGD","IT","LU2517655374.HKD","SD","BK4104"],"gpt_icon":0},{"id":"2483886856","title":"Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483886856","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483886856?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:06","pubTimestamp":1731532011,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUAB5MLHV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INTS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INTS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INTS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":5,"updateTime":1737000000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/INTS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"INTS","date":"2025-04-21","current":-1.72638,"percent":0.992991,"low":-15.25821,"twenty":-7.625735,"median":-4.806475,"eighty":-2.407402,"high":-1.625368,"avg":-5.372942,"sd":3.174297,"marketCap":28084748},"quantilePoints":[{"date":"2022-10-20","current":-9.173693,"twenty":-9.173693,"median":-9.173693,"eighty":-9.173693,"marketCap":80934718},{"date":"2023-07-07","current":-12.000673,"twenty":-12.000673,"median":-11.893737,"eighty":-9.173693,"marketCap":78596262},{"date":"2023-07-14","current":-11.805305,"twenty":-12.014248,"median":-11.893737,"eighty":-11.600651,"marketCap":77316730},{"date":"2023-07-21","current":-12.682867,"twenty":-12.306769,"median":-11.947205,"eighty":-11.660654,"marketCap":83064168},{"date":"2023-07-28","current":-11.867988,"twenty":-12.682867,"median":-12.014248,"eighty":-11.805305,"marketCap":77727261},{"date":"2023-08-04","current":-12.81868,"twenty":-12.682867,"median":-12.066484,"eighty":-11.867988,"marketCap":83953652},{"date":"2023-08-11","current":-12.933599,"twenty":-12.933599,"median":-12.306769,"eighty":-11.888882,"marketCap":84706293},{"date":"2023-08-18","current":-9.652146,"twenty":-12.81868,"median":-12.1197,"eighty":-11.660654,"marketCap":80327292},{"date":"2023-08-25","current":-9.800135,"twenty":-12.808233,"median":-12.000673,"eighty":-9.800135,"marketCap":81558886},{"date":"2023-09-01","current":-9.487714,"twenty":-12.770623,"median":-11.912204,"eighty":-9.783692,"marketCap":78958855},{"date":"2023-09-08","current":-9.093078,"twenty":-12.755579,"median":-11.893737,"eighty":-9.638992,"marketCap":75674604},{"date":"2023-09-15","current":-8.073601,"twenty":-12.70794,"median":-11.836647,"eighty":-9.487714,"marketCap":67190291},{"date":"2023-09-22","current":-6.034647,"twenty":-12.632721,"median":-11.600651,"eighty":-9.000996,"marketCap":50221663},{"date":"2023-09-29","current":-6.626601,"twenty":-12.586753,"median":-9.923459,"eighty":-8.293939,"marketCap":55148039},{"date":"2023-10-06","current":-7.251442,"twenty":-12.570873,"median":-9.800135,"eighty":-7.560574,"marketCap":60348102},{"date":"2023-10-13","current":-6.626601,"twenty":-12.448015,"median":-9.783692,"eighty":-7.192246,"marketCap":55148039},{"date":"2023-10-20","current":-4.636976,"twenty":-12.331842,"median":-9.61926,"eighty":-6.745518,"marketCap":38589943},{"date":"2023-10-23","current":-4.96584,"twenty":-12.319306,"median":-9.578152,"eighty":-6.686849,"marketCap":41326818},{"date":"2023-11-03","current":-4.932954,"twenty":-12.157898,"median":-9.487714,"eighty":-6.567406,"marketCap":41053131},{"date":"2023-11-10","current":-4.609845,"twenty":-12.119112,"median":-9.173693,"eighty":-6.48519,"marketCap":38364150},{"date":"2023-11-17","current":-3.237228,"twenty":-12.035142,"median":-8.862874,"eighty":-6.287872,"marketCap":28737191},{"date":"2023-11-24","current":-3.590621,"twenty":-12.006103,"median":-8.517567,"eighty":-5.189368,"marketCap":31874301},{"date":"2023-12-01","current":-3.784438,"twenty":-11.971208,"median":-8.209257,"eighty":-5.01517,"marketCap":33594828},{"date":"2023-12-08","current":-6.177413,"twenty":-11.939029,"median":-7.613192,"eighty":-5.01517,"marketCap":54837508},{"date":"2023-12-15","current":-12.447487,"twenty":-12.056037,"median":-8.209257,"eighty":-5.034902,"marketCap":110497578},{"date":"2023-12-22","current":-9.544103,"twenty":-12.056037,"median":-8.517567,"eighty":-5.074891,"marketCap":84723949},{"date":"2023-12-29","current":-12.200391,"twenty":-12.097826,"median":-8.854652,"eighty":-5.093498,"marketCap":108304078},{"date":"2024-01-05","current":-12.586479,"twenty":-12.221667,"median":-9.093078,"eighty":-5.095649,"marketCap":111731422},{"date":"2024-01-12","current":-9.080797,"twenty":-12.136622,"median":-9.173576,"eighty":-5.162954,"marketCap":80611136},{"date":"2024-01-19","current":-7.443783,"twenty":-12.119504,"median":-9.086938,"eighty":-5.189368,"marketCap":66079197},{"date":"2024-01-26","current":-6.94959,"twenty":-12.056037,"median":-8.862874,"eighty":-5.265897,"marketCap":61692196},{"date":"2024-02-02","current":-7.706323,"twenty":-12.006103,"median":-8.582973,"eighty":-5.358906,"marketCap":68409791},{"date":"2024-02-09","current":-5.497898,"twenty":-11.971208,"median":-8.279141,"eighty":-5.454656,"marketCap":48805382},{"date":"2024-02-16","current":-4.67939,"twenty":-11.939029,"median":-8.106172,"eighty":-5.189368,"marketCap":41539412},{"date":"2024-02-23","current":-4.63306,"twenty":-11.915897,"median":-7.791263,"eighty":-5.065946,"marketCap":41128131},{"date":"2024-03-01","current":-5.714107,"twenty":-11.893737,"median":-7.613192,"eighty":-5.065946,"marketCap":50724694},{"date":"2024-03-08","current":-8.617491,"twenty":-11.891795,"median":-7.659757,"eighty":-5.094215,"marketCap":76498323},{"date":"2024-03-15","current":-6.42451,"twenty":-11.880524,"median":-7.613192,"eighty":-5.12966,"marketCap":57031008},{"date":"2024-03-22","current":-7.168217,"twenty":-11.842915,"median":-7.462714,"eighty":-5.183371,"marketCap":75538667},{"date":"2024-03-28","current":-6.569781,"twenty":-11.793205,"median":-7.382998,"eighty":-5.190398,"marketCap":69232353},{"date":"2024-04-05","current":-6.062412,"twenty":-11.727976,"median":-7.320234,"eighty":-5.219219,"marketCap":63885696},{"date":"2024-04-12","current":-5.919308,"twenty":-11.648653,"median":-7.270395,"eighty":-5.328019,"marketCap":62377665},{"date":"2024-04-19","current":-4.956607,"twenty":-11.467325,"median":-7.168217,"eighty":-5.219219,"marketCap":52232726},{"date":"2024-04-26","current":-5.106216,"twenty":-10.872247,"median":-7.057617,"eighty":-5.181486,"marketCap":53809304},{"date":"2024-05-03","current":-5.203787,"twenty":-10.575732,"median":-7.004794,"eighty":-5.110119,"marketCap":54837508},{"date":"2024-05-10","current":-4.89156,"twenty":-10.334812,"median":-6.920091,"eighty":-5.07751,"marketCap":51547257},{"date":"2024-05-17","current":-5.064674,"twenty":-10.138832,"median":-6.816961,"eighty":-5.04775,"marketCap":69917822},{"date":"2024-05-24","current":-5.034882,"twenty":-10.040205,"median":-6.769756,"eighty":-5.01517,"marketCap":69506541},{"date":"2024-05-31","current":-4.905782,"twenty":-10.013896,"median":-6.720408,"eighty":-4.982612,"marketCap":67724322},{"date":"2024-06-07","current":-4.945811,"twenty":-9.945635,"median":-6.626601,"eighty":-4.965367,"marketCap":68276920},{"date":"2024-06-14","current":-4.747756,"twenty":-9.859151,"median":-6.577272,"eighty":-4.943699,"marketCap":65542772},{"date":"2024-06-21","current":-4.638498,"twenty":-9.834825,"median":-6.527942,"eighty":-4.905297,"marketCap":64034465},{"date":"2024-06-28","current":-4.887408,"twenty":-9.833021,"median":-6.527942,"eighty":-4.896744,"marketCap":67470661},{"date":"2024-07-05","current":-4.817184,"twenty":-9.806712,"median":-6.504734,"eighty":-4.887289,"marketCap":66501232},{"date":"2024-07-12","current":-4.986137,"twenty":-9.800135,"median":-6.468725,"eighty":-4.878216,"marketCap":68833622},{"date":"2024-07-15","current":-5.055665,"twenty":-9.800135,"median":-6.445726,"eighty":-4.87855,"marketCap":69793453},{"date":"2024-08-02","current":-4.807351,"twenty":-9.796846,"median":-6.435118,"eighty":-4.877213,"marketCap":66365484},{"date":"2024-08-09","current":-4.588835,"twenty":-9.783692,"median":-6.41284,"eighty":-4.86516,"marketCap":63348871},{"date":"2024-08-16","current":-3.955696,"twenty":-9.783692,"median":-6.339457,"eighty":-4.820512,"marketCap":59632119},{"date":"2024-08-23","current":-3.896315,"twenty":-9.757383,"median":-6.270563,"eighty":-4.807351,"marketCap":58736948},{"date":"2024-08-30","current":-3.86434,"twenty":-9.645569,"median":-6.204474,"eighty":-4.781352,"marketCap":58254933},{"date":"2024-09-06","current":-3.910018,"twenty":-9.61926,"median":-6.112191,"eighty":-4.747756,"marketCap":58943526},{"date":"2024-09-13","current":-3.837391,"twenty":-9.544103,"median":-6.034647,"eighty":-4.707926,"marketCap":57848664},{"date":"2024-09-20","current":-3.727307,"twenty":-9.537044,"median":-5.97785,"eighty":-4.668296,"marketCap":56189156},{"date":"2024-09-27","current":-3.316207,"twenty":-9.52866,"median":-5.925812,"eighty":-4.63306,"marketCap":49991822},{"date":"2024-10-04","current":-3.2888,"twenty":-9.487714,"median":-5.784184,"eighty":-4.588835,"marketCap":49578667},{"date":"2024-10-11","current":-3.037299,"twenty":-9.487714,"median":-5.559672,"eighty":-4.472545,"marketCap":45787276},{"date":"2024-10-18","current":-2.923378,"twenty":-9.487714,"median":-5.461423,"eighty":-4.216084,"marketCap":44069926},{"date":"2024-10-25","current":-2.923378,"twenty":-9.26612,"median":-5.333882,"eighty":-3.973967,"marketCap":44069926},{"date":"2024-10-31","current":-2.786345,"twenty":-9.192178,"median":-5.307863,"eighty":-3.960154,"marketCap":42004148},{"date":"2024-11-08","current":-2.941649,"twenty":-9.173693,"median":-5.199834,"eighty":-3.926462,"marketCap":44345363},{"date":"2024-11-15","current":-2.689442,"twenty":-9.173505,"median":-5.189027,"eighty":-3.893574,"marketCap":43725630},{"date":"2024-11-22","current":-2.507825,"twenty":-9.109154,"median":-5.115973,"eighty":-3.863938,"marketCap":40772862},{"date":"2024-11-29","current":-2.717615,"twenty":-9.085709,"median":-5.101291,"eighty":-3.84881,"marketCap":44185701},{"date":"2024-12-06","current":-2.321954,"twenty":-9.052999,"median":-5.073692,"eighty":-3.799491,"marketCap":37752650},{"date":"2024-12-13","current":-1.917562,"twenty":-8.931511,"median":-5.06017,"eighty":-3.723653,"marketCap":31177648},{"date":"2024-12-20","current":-1.857563,"twenty":-8.853008,"median":-5.047673,"eighty":-3.619065,"marketCap":30202120},{"date":"2024-12-27","current":-1.764685,"twenty":-8.767209,"median":-5.021654,"eighty":-3.573099,"marketCap":28692014},{"date":"2025-01-03","current":-1.625368,"twenty":-8.642201,"median":-5.01517,"eighty":-3.513045,"marketCap":26426855},{"date":"2025-01-10","current":-1.838802,"twenty":-8.617491,"median":-5.008645,"eighty":-3.463472,"marketCap":29897078},{"date":"2025-01-17","current":-2.572725,"twenty":-8.517567,"median":-4.984374,"eighty":-3.373331,"marketCap":41829936},{"date":"2025-01-24","current":-2.370715,"twenty":-8.346557,"median":-4.965604,"eighty":-3.310726,"marketCap":38545455},{"date":"2025-01-31","current":-2.053117,"twenty":-8.284074,"median":-4.956607,"eighty":-3.212827,"marketCap":33381630},{"date":"2025-02-07","current":-2.238919,"twenty":-8.253306,"median":-4.940989,"eighty":-3.06772,"marketCap":36402592},{"date":"2025-02-14","current":-2.015957,"twenty":-8.160869,"median":-4.905782,"eighty":-3.026792,"marketCap":32777437},{"date":"2025-02-21","current":-2.043827,"twenty":-8.138995,"median":-4.896744,"eighty":-3.006493,"marketCap":33230582},{"date":"2025-02-28","current":-2.099568,"twenty":-8.099657,"median":-4.889484,"eighty":-2.934341,"marketCap":34136870},{"date":"2025-03-07","current":-2.146018,"twenty":-8.038556,"median":-4.87855,"eighty":-2.919724,"marketCap":34892111},{"date":"2025-03-14","current":-2.159953,"twenty":-8.005927,"median":-4.871913,"eighty":-2.813752,"marketCap":35118683},{"date":"2025-03-21","current":-1.801034,"twenty":-7.907089,"median":-4.866947,"eighty":-2.682321,"marketCap":29299223},{"date":"2025-03-28","current":-1.800101,"twenty":-7.780452,"median":-4.846639,"eighty":-2.622879,"marketCap":29284042},{"date":"2025-04-04","current":-1.82903,"twenty":-7.718678,"median":-4.817184,"eighty":-2.548971,"marketCap":29754652},{"date":"2025-04-11","current":-1.810366,"twenty":-7.669259,"median":-4.807351,"eighty":-2.494707,"marketCap":29451033},{"date":"2025-04-17","current":-1.735712,"twenty":-7.632006,"median":-4.806913,"eighty":-2.414832,"marketCap":28236557},{"date":"2025-04-21","current":-1.72638,"twenty":-7.625735,"median":-4.806475,"eighty":-2.407402,"marketCap":28084748}],"updateTime":1745358542670}}}